PROJECT 2: ABSTRACT Cure or control of HIV infection in the absence of antiretroviral therapy (ART) will likely require host immune responses that eliminate HIV-infected cells or prevent new rounds of viral replication. A key problem is the ability of HIV to target and destroy CD4 T-cells that coordinate adaptive immune responses. Sangamo BioSciences together with the Hoxie lab at UPenn have shown that coreceptors (CoR) CXCR4 and CCR5, when modified to contain a C34 peptide from the gp41 HR2 domain conjugated to their amino termini, become potent trans-dominant inhibitors of HIV-1 entry. Inhibition occurs at ratios of <1:10 C34-conjugated to unconjugated CoR, respectively, and occurs irrespective of viral tropism, for multple clades, and for viruses that are resistant to soluble T20. The breadth and potency of HIV inhibition was demonstrated in vitro on primary CD4 T-cells where cells expressing C34-CoR showed a clear survival advantage during HIV-1 infection. We hypothesize that stable expression of C34-conjugated CoR on peripheral CD4 T-cells in vivo will lead to HIV resistance, enabling immune responses to control virus in the absence of ART and to target viral reservoirs following cessation of ART. This project will advance these observations with three Specific Aims: 1) The mechanisms underlying this extremely potent trans-dominant inhibition by C34-CoR will be explored by determining the role of CoR trafficking and positioning of the C34-peptide; 2) Resistance to HIV-1 has also been conferred using a novel gene editing approach to insert the C34 peptide into the endogenous CXCR4 gene, and will be studied in primary CD4 cells in vitro and in humanized mice when this C34-edited CoR is expressed under physiologic control of its endogenous promoter; and 3) Anticipated viral escape from C34- CoR inhibition will be assessed in vitro and in vivo to identify mutations, determine the underlying mechanisms, and assess barriers and fitness costs that can inform clinical studies in which C34-CoRs are expressed on autologous CD4 T-cells and used in cell-based therapeutic studies. The preliminary studies for Project 2 have provided the rationale for translating the potency of C34-CoR inhibition of HIV-1 to a human trial (Project 1), and its three Specific Aims will provide a mechanistic understanding of this effect at the cellular, virologic, and molecular levels that will enable further advances to be made. In addition, this approach for protecting CD4 T- cells from HIV infection, coupled with approaches to direct effector T-cells to virally-infected targets (Project 3) and to sustain these responses in vivo (Project 4), position this Program Project for developing a new paradigm of HIV control and possibly eradication.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19AI117950-02
Application #
9052707
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
2016-04-01
Budget End
2017-03-31
Support Year
2
Fiscal Year
2016
Total Cost
Indirect Cost
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Fraietta, Joseph A; Nobles, Christopher L; Sammons, Morgan A et al. (2018) Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. Nature 558:307-312
Medvec, Andrew R; Ecker, Christopher; Kong, Hong et al. (2018) Improved Expansion and In Vivo Function of Patient T Cells by a Serum-free Medium. Mol Ther Methods Clin Dev 8:65-74
Clarke, Erik L; Connell, A Jesse; Six, Emmanuelle et al. (2018) T cell dynamics and response of the microbiota after gene therapy to treat X-linked severe combined immunodeficiency. Genome Med 10:70
Stelekati, Erietta; Chen, Zeyu; Manne, Sasikanth et al. (2018) Long-Term Persistence of Exhausted CD8 T Cells in Chronic Infection Is Regulated by MicroRNA-155. Cell Rep 23:2142-2156
Ecker, Christopher; Riley, James L (2018) Translating In Vitro T Cell Metabolic Findings to In Vivo Tumor Models of Nutrient Competition. Cell Metab 28:190-195
Ecker, Christopher; Guo, Lili; Voicu, Stefana et al. (2018) Differential Reliance on Lipid Metabolism as a Salvage Pathway Underlies Functional Differences of T Cell Subsets in Poor Nutrient Environments. Cell Rep 23:741-755
Maldini, Colby R; Ellis, Gavin I; Riley, James L (2018) CAR T cells for infection, autoimmunity and allotransplantation. Nat Rev Immunol 18:605-616
Bengsch, Bertram; Ohtani, Takuya; Khan, Omar et al. (2018) Epigenomic-Guided Mass Cytometry Profiling Reveals Disease-Specific Features of Exhausted CD8 T Cells. Immunity 48:1029-1045.e5
Veenhuis, Rebecca T; Kwaa, Abena K; Garliss, Caroline C et al. (2018) Long-term remission despite clonal expansion of replication-competent HIV-1 isolates. JCI Insight 3:
Chen, Gang; Huang, Alexander C; Zhang, Wei et al. (2018) Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature 560:382-386

Showing the most recent 10 out of 27 publications